US FDA Convinced: Cosmetic Adverse Event Reports Aren’t Telling Whole Story

Linda Katz, director of the FDA’s cosmetics office, says to “stay tuned” for federal legislative developments in 2022, maintaining her position that voluntary adverse-event reporting paints an incomplete picture of consumers’ experience with cosmetic products across the US.

Sign outside of FDA's headquarters in White Oak, MD

More from United States

More from North America